Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

MSCI Emerging Markets Index / Technical Analysis

Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point, concerns surrounding the Wuhan coronavirus have led to some market setbacks and deterioration in market indicators, however they have not resulted in breakdowns. This is true even for areas of the market most-directly affected, including China (MSCI China) and emerging markets (MSCI EM). For these reasons and, as long as there is no significant additional damage, we view recent weakness as a buying opportunity - especially within EM. We see coronavirus concerns as helping correct the excess bullish sentiment and optimism in the short-term.

Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point, concerns surrounding the Wuhan coronavirus have led to some market setbacks and deterioration in market indicators, however they have not resulted in breakdowns. This is true even for areas of the market most-directly affected, including China (MSCI China) and emerging markets (MSCI EM). For these reasons and, as long as there is no significant additional damage, we view recent weakness as a buying opportunity - especially within EM. We see coronavirus concerns as helping correct the excess bullish sentiment and optimism in the short-term.

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Thematic (Sector/Industry)

<a href="https://www.smartkarma.com/entities/21112" target="_blank" data-smartkarma-citation="entities:21112:1">Galapagos NV (GLPG NA)</a> seems to have got some investor attention after the successful results of <a href="https://www.smartkarma.com/entities/7410" target="_blank" data-smartkarma-citation="entities:7410:1">Celgene Corp (CELG US)</a> anti-inflammatory product candidate for the treatment of Crohn's disease. Galapagos' filgotinib is being developed in partnership with <a href="https://www.smartkarma.com/entities/973" target="_blank" data-smartkarma-citation="entities:973:1">Gilead Sciences Inc (GILD US)</a> and showed 48% remission and 67% clinical response in Crohn's disease. A phase 3 trial of the drug will start soon. Our sentiment on Galapagos stock: neutral. <a href="https://www.smartkarma.com/entities/8669" target="_blank" data-smartkarma-citation="entities:8669:1">Atara Biotherapeutics Inc (ATRA US)</a> received PRIME…

Galapagos NV (GLPG NA) seems to have got some investor attention after the successful results of Celgene Corp (CELG US) anti-inflammatory product candidate for the treatment of Crohn's disease. Galapagos' filgotinib is being developed in partnership with Gilead Sciences Inc (GILD US) and showed 48% remission and 67% clinical response in Crohn's disease. A phase 3 trial of the drug will start soon. Our sentiment on Galapagos stock: neutral. Atara Biotherapeutics Inc (ATRA US) received PRIME…

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update

Germany

Sartorius AG manufactures and markets precision electronic equipment and components.  The Company produces precision scales for laboratory and industrial uses and electrochemistry.  Sartorius manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation, and purification.  The Company markets its products worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sartorius AG (SRT GR)

EM Pullback Opportunity

Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point,...

Vermilion Research

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update

Galapagos NV (GLPG NA) seems to have got some investor attention after the successful results of Celgene Corp (CELG US) anti-inflammatory product...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)